Diagnosing and Treating Familial Chylomicronemia Syndrome: Perspectives from a Clinical Forum

The triglyceride treatment landscape is shifting quickly, and nowhere is that more apparent than in the management of severe hypertriglyceridemia.

As new therapies enter practice, clinicians across specialties are being asked to sharpen their index of suspicion for rare, genetic forms of the disease that conventional lipid-lowering agents fail to touch.

That evolving picture framed a clinical forum held May 6, 2026, in Boston, Massachusetts, where Nihar Desai, MD, MPH, of Yale School of Medicine, led cardiologists, endocrinologists, a nephrologist, and primary care physicians through a discussion of familial chylomicronemia syndrome (FCS), an autosomal recessive disorder driven by loss of lipoprotein lipase (LPL) activity.

FCS results from complete or partial LPL deficiency, most often due to biallelic loss-of-function variants in the LPL gene, allowing chylomicrons and very low-density lipoprotein to accumulate in the bloodstream.¹

The condition is rare, affecting an estimated 1 to 19 per million people, and typically presents in childhood with fasting triglycerides persistently at or above 880 mg/dL. That distinguishes it from multifactorial chylomicronemia syndrome, a more common, largely polygenic condition presenting in adulthood that responds at least modestly to statins, fibrates, or omega-3 therapy, unlike FCS.¹

Participants described the diagnostic odyssey many patients with FCS experience before a clinician connects the dots. One described a patient diagnosed with severe hypertriglyceridemia at age 7 whose levels ran between 4000 and 6000 mg/dL by age 24, despite trials of conventional agents. Desai noted that patients are seen by an average of five providers before a correct diagnosis is made, nearly half are initially misdiagnosed, and about three in four are diagnosed within the first decade of life.

The clinical stakes of delayed recognition are significant. Patients with FCS face an estimated 60% to 90% lifetime risk of acute pancreatitis, with recurrent episodes in more than half of patients and mortality reaching 5% to 6%.² Desai cited survey data showing two-thirds of patients report the condition significantly affects self-worth, emotional well-being, sleep, and mental functioning.

Participants discussed formal scoring systems, including the North American FCS calculator and the European diagnostic scoring system, as tools to formalize clinical suspicion, though several noted family history can be an unreliable prompt given the autosomal recessive inheritance pattern, which often produces sporadic-appearing cases.

Participants converged on triglyceride thresholds as practical referral triggers. Several described referring patients above 500 mg/dL to a lipid specialist, while one nephrologist reserved referral for suspected genetic cases even below that threshold. Barriers to genetic testing were recurring, including cost, appointment burden, and inconsistent insurance coverage, though at least one commercial testing program offers no-cost sequencing for patients with sufficient clinical suspicion.

Desai reviewed current standard-of-care lifestyle measures, including a very-low-fat diet of 10% to 15% of calories, fat-soluble vitamin supplementation, alcohol abstinence, and selective use of medium-chain triglyceride oil, which does not form chylomicrons. Several participants said these measures are difficult to sustain long-term, citing limited access to purified medium-chain triglyceride oil products and the pervasiveness of dietary fat in daily life.

The forum's central focus was the pharmacologic landscape targeting apolipoprotein C-III (APOC3), a key inhibitor of LPL activity and of LPL-independent chylomicron clearance.

Two APOC3-directed therapies are now FDA-approved:

olezarsen, an antisense oligonucleotide dosed every 4 weeks and approved in December 2024

plozasiran, a small interfering RNA dosed every 3 months and approved in November 2025.

Both agents degrade APOC3 messenger RNA before the protein is produced, restoring chylomicron clearance through LPL-dependent and LPL-independent pathways, Desai explained.³,⁴

In the phase 3 BALANCE trial, olezarsen 80 mg reduced triglycerides by approximately 40% to 45% at steady state versus placebo, with serious adverse events in 14% of the 80-mg group compared with 39% of placebo.³

In the phase 3 PALISADE trial, plozasiran produced roughly 70% reductions in triglycerides and 90% suppression of APOC3 by months 10 and 12, with an 83% relative reduction in acute pancreatitis risk versus placebo.⁴

Desai noted the olezarsen trial enrolled only genetically confirmed FCS, while the plozasiran trial allowed a broader population including clinically diagnosed, symptomatic persistent chylomicronemia, a distinction participants said could influence therapy selection absent confirmed biallelic variants.

Several participants described relying on dedicated pharmacy teams to navigate prior authorization and patient assistance programs, without which access remained a persistent obstacle. One participant said cost and coverage, more than clinical uncertainty, remain the primary barriers to broader adoption, while another wanted longer-term, real-world phase 4 tolerability data before feeling fully comfortable prescribing.

Participants closed by reflecting on how far management options have advanced, and on the importance of building referral pathways before a patient's first pancreatitis episode rather than after. Desai emphasized that with two approved therapies now available, the task facing clinicians outside lipid subspecialty practice is recognizing the syndrome early enough to act, since diagnosis alone can now change these patients' clinical trajectory.

References

1. Brinton EA, Hegele RA, Gaudet D, et al. Familial chylomicronemia syndrome. Atherosclerosis. 2025;403:119114.

2. Sanchez RJ, Ge W, Wei W, Ponda D, Rajpathak S. The association of triglyceride levels with the incidence of initial and recurrent acute pancreatitis. Lipids Health Dis. 2021;20:72.

3. Stroes ESG, Alexander VJ, Karwatowska-Prokopczuk E, et al. Olezarsen, acute pancreatitis, and familial chylomicronemia syndrome. N Engl J Med. 2024;390(19):1781-1792.

4. Watts GF, Gidding SS, Mata P, et al. Plozasiran for managing persistent chylomicronemia and familial chylomicronemia syndrome. N Engl J Med. 2025;392(2):127-137.